Cosmetic Ingredient Review Report Status
This article was originally published in The Rose Sheet
Executive Summary
Chart: Data compiled by the Rose Sheet from information in CIR reports following the Expert Panel's Sept. 11-12 meeting.
You may also be interested in...
CIR News In Brief: No Conclusion Reached On PHMB; Endocrine Activity Guidance; More
At its Sept. 11-12 meeting in Washington, the Cosmetic Ingredient Review Expert Panel finalized reports for various protein and peptide ingredient families, among others, and advanced six tentative reports. The panel issued a tentative insufficient data conclusion for broad-spectrum preservative polyaminopropyl biguanide, with concerns about sensitization continuing to weigh on the group.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.